Lipella Pharmaceuticals Inc. (LIPO) Tuesday reported positive topline data from Phase 2a study of LP-310 for the treatment of oral lichen planus (OLP). Following the news, the company's shares were more than 65 percent up in pre-market.
OLP is a chronic inflammatory condition that targets mucous membranes in the mouth, causing pain.
In the study, OLP patients were treated with twice-daily dose of 0.25 mg of LP-310. Results from the study showed clinically meaningful reductions in pain, ulceration, and inflammation in patients treated with LP-310. Further, there were no reports of product-related serious adverse events.
A Phase 2a study with higher treatment dose is underway.
Lipella stock had closed at $3.05, down 0.65 percent on Monday. It has traded in the range of $2.21 - 12.00 in the last 1 year.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.